Immuneering Corp IMRX
We take great care to ensure that the data presented and summarized in this overview for Immuneering Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMRX
View all-
Vanguard Group Inc Valley Forge, PA2.42MShares$15.5 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$11.5 Million0.0% of portfolio
-
Exodus Point Capital Management, LP New York, NY1.52MShares$9.71 Million0.11% of portfolio
-
Logos Global Management LP San Francisco, CA950KShares$6.08 Million0.72% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il943KShares$6.04 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY550KShares$3.52 Million1.56% of portfolio
-
Black Rock Inc. New York, NY533KShares$3.41 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA514KShares$3.29 Million0.0% of portfolio
-
Occam Crest Management LP Darien, CT498KShares$3.19 Million2.12% of portfolio
-
Monashee Investment Management LLC Boston, MA300KShares$1.92 Million3.15% of portfolio
Latest Institutional Activity in IMRX
Top Purchases
Top Sells
About IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Insider Transactions at IMRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2025
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
7,500
+4.57%
|
$45,000
$6.67 P/Share
|
|
Oct 01
2025
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
300
+1.08%
|
$1,800
$6.39 P/Share
|
|
Oct 01
2025
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Open market or private purchase
|
Direct |
800
+3.31%
|
$4,800
$6.38 P/Share
|
|
Oct 01
2025
|
Michael Bookman CHIEF LEGAL OFFICER, SECRETARY |
BUY
Open market or private purchase
|
Direct |
1,020
+17.32%
|
$6,120
$6.83 P/Share
|
|
Sep 30
2025
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
7,500
+4.78%
|
$52,500
$7.03 P/Share
|
|
Sep 29
2025
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
5,000
+3.41%
|
$35,000
$7.18 P/Share
|
|
Sep 15
2025
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,815
+34.39%
|
$11,815
$1.43 P/Share
|
|
Sep 15
2025
|
Mallory Morales Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,497
+34.74%
|
$14,497
$1.43 P/Share
|
|
Sep 15
2025
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,880
+3.82%
|
$14,880
$1.43 P/Share
|
|
Jul 02
2025
|
Diana Hausman Director |
BUY
Open market or private purchase
|
Indirect |
3,000
+50.0%
|
$9,000
$3.62 P/Share
|
|
Jul 02
2025
|
Diana Hausman Director |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$7,500
$3.6 P/Share
|
|
Jul 02
2025
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Open market or private purchase
|
Direct |
700
+6.12%
|
$2,100
$3.57 P/Share
|
|
Jul 02
2025
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
7,015
+0.3%
|
$21,045
$3.53 P/Share
|
|
Jul 01
2025
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
2,985
+0.13%
|
$8,955
$3.38 P/Share
|
|
Jun 27
2025
|
Thomas J. Schall Director |
BUY
Open market or private purchase
|
Direct |
9,500
+15.23%
|
$28,500
$3.66 P/Share
|
|
Jun 23
2025
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
6,007
+1.64%
|
$12,014
$2.43 P/Share
|
|
Jun 20
2025
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
7,415
+2.06%
|
$14,830
$2.7 P/Share
|
|
Jun 20
2025
|
Harold Eugene Brakewood Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
1,900
+24.68%
|
$3,800
$2.53 P/Share
|
|
Jun 18
2025
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+15.45%
|
$50,000
$2.53 P/Share
|
|
Jun 18
2025
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
21,000
+0.9%
|
$42,000
$2.39 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 150K shares |
|---|---|
| Grant, award, or other acquisition | 41.2K shares |